Filtered By:
Condition: Heart Valve Disease
Education: Study
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 330 results found since Jan 2013.
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Clinical outcomes of the ACURATE neo2 transcatheter heart valve: a prospective, multicenter, observational, post-market surveillance study
CONCLUSIONS: The study results support the safety and efficacy of TAVI with ACURATE neo2 in patients in routine clinical practice.PMID:36440588 | DOI:10.4244/EIJ-D-22-00914
Source: EuroIntervention - November 28, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Won-Keun Kim Corrado Tamburino Helge M öllmann Matteo Montorfano Julia Ellert-Gregersen Tanja K Rudolph Nicolas M Van Mieghem Michael Hilker Ignacio J Amat-Santos Christian Juhl Terkelsen Anna Sonia Petronio Pieter R Stella Matthias G ötberg Andreas R Source Type: research
Pearls, pitfalls, and surgical indications of the Intuity TM heart valve: A rapid deployment bioprosthesis. A systematic review of the literature
ConclusionsThis manuscript provides a 360 ° overview of the current rapid deployments, sutureless, and TAVR prosthesis.
Source: Journal of Cardiac Surgery - November 20, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Aleksander Dokollari,
Gianluca Torregrossa,
Serge Sicouri,
Altin Veshti,
Rafik Margaryan,
Matteo Cameli,
Giulia Elena Mandoli,
Massimo Maccherini,
Gianfranco Montesi,
Francesco Cabrucci,
Lindita Coku,
Rakesh Arora,
Qiao Ri Li,
Massimo Bonacch Tags: REVIEW Source Type: research
Statins Reduce Bleeding Risk in Patients Taking Oral Anticoagulants for Nonvalvular Atrial Fibrillation: A Retrospective Registry Study
ConclusionsStatins significantly reduced the risk of major bleeding, all-cause mortality, and ischemic events in patients with NVAF taking OACs. Their additive benefits should be considered in routine practice and thus be further researched.
Source: American Journal of Cardiovascular Drugs - November 16, 2022 Category: Cardiology Source Type: research
Transcatheter heart valve selection in patients with low ejection fraction and aortic stenosis
ConclusionThe choice of THV in patients with severe AS and systolic dysfunction must be weighed on a case-by-case basis.
Source: Journal of Cardiac Surgery - November 15, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Ahmad Mustafa,
Chad Kliger,
Luigi Pirelli,
Arber Kodra,
Denny Wang,
Priyanka Singh,
Paley Arnone,
Apurva Patel,
Shangyi Liu,
Efstathia Mihelis,
Elana Koss,
Sean Wilson,
Gregory Maniatis,
Mohammed Imam,
Puneet Gandotra,
Robert Kalimi,
Azhar Tags: ORIGINAL ARTICLE Source Type: research
Association between Acid-Suppressive Drugs and Clinical Outcomes in Patients with Nonvalvular Atrial Fibrillation
ConclusionsASDs were significantly associated with all-cause mortality in patients with NVAF taking OACs.
Source: Drugs in R&D - July 19, 2022 Category: Drugs & Pharmacology Source Type: research
Heart surgery and simultaneous carotid endarterectomy - 10-years single-center experience
CONCLUSION: Within the reported patient population of coronary artery heart disease and significant internal carotid stenosis, a one-time approach with CABG or heart-valve surgery and CEA is safe and feasible as justified by clinical and neurological postoperative outcomes.PMID:35841145 | DOI:10.1177/02676591221114953
Source: Perfusion - July 16, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Stephen Gerfer Borko Ivanov Ihor Krasivskyi Ilija Djordjevic Christopher Gaisendrees Soi Avgeridou Ferdinand Kuhn-R égnier Navid Mader Parwis Rahmanian Axel Kr öner Elmar Kuhn Thorsten Wahlers Source Type: research
Effect of β‐blocker on patients with moderate functional mitral regurgitation undergoing surgical aortic valve replacement
ConclusionsThe administration of BB after SAVR was not associated with lower risk of MACCE for patients of severe aortic valve disease complicated with moderate FMR, but was potentially beneficial for improving FMR.
Source: ESC Heart Failure - July 13, 2022 Category: Cardiology Authors: Xieraili Tiemuerniyazi,
Yifeng Nan,
Yangwu Song,
Ziang Yang,
Wei Zhao,
Fei Xu,
Wei Feng Tags: Original Article Source Type: research
Severe Libman –Sacks endocarditis complicating antiphospholipid syndrome: a retrospective analysis of 23 operated cases
ConclusionSevere HVD leading to surgery was strongly associated with thrombotic APS, especially arterial phenotypes. Half of the reported patients presented cerebral stroke complicating the HVD. Valvular surgery carried a significant risk of CAPS.
Source: Rheumatology - June 10, 2022 Category: Rheumatology Source Type: research
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
Efficacy and Safety of Postdilation for a Self-Expanding Transcatheter Heart Valve
CONCLUSION: For transfemoral TAVR using the Acurate neo/neo2, BPD effectively reduces relevant PVR and decreases the risk of PPM without increasing adverse events. Transcatheter heart valve damage associated with BPD is rare, commonly avoidable, and does not jeopardize the net benefit of BPD.PMID:35593542
Source: The Journal of Invasive Cardiology - May 20, 2022 Category: Cardiology Authors: Won-Keun Kim Matthias Renker Holger Nef Helge M öllmann Thomas Walther Yeong-Hoon Choi Christian W Hamm Source Type: research
